MMP3 in Severe COVID-19: A Biomarker or Therapeutic Target?

Identifying novel therapies is a critical need in the treatment of coronavirus disease-19 (COVID-19) and acute respiratory distress syndrome (ARDS). Stromelysin-1, also known as matrixmetalloproteinase 3 (MMP3), has been investigated as a diagnostic biomarker and a potential pharmacological target. Here, we discuss the recent findings of Gelzo et al. in the context of additional MMP3 investigations to delineate its exact role in diagnosis, prognostication, and phenotyping, in addition to its promising role as a therapeutic target in COVID-19-associated respiratory failure. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Citation

Sultan Almuntashiri, Duo Zhang, Payaningal R Somanath, Andrea Sikora. MMP3 in Severe COVID-19: A Biomarker or Therapeutic Target? Infectious disorders drug targets. 2023;23(1):e190622206159

Mesh Tags

Substances

PMID: 35726419

search → result